Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
Sharana Mahomed, Nigel Garrett, Edmund V. Capparelli, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 3, pp. 510-520
Open Access | Times Cited: 21

Showing 21 citing articles:

Antiviral neutralizing antibodies: from in vitro to in vivo activity
Dennis R. Burton
Nature reviews. Immunology (2023) Vol. 23, Iss. 11, pp. 720-734
Open Access | Times Cited: 61
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial
Sharana Mahomed, Nigel Garrett, Edmund V. Capparelli, et al.
The Lancet HIV (2023) Vol. 10, Iss. 4, pp. e230-e243
Closed Access | Times Cited: 19
Subcutaneous delivery of an antibody against SARS-CoV-2 from a supramolecular hydrogel depot
Catherine M. Kasse, Anthony C. Yu, Abigail E. Powell, et al.
Biomaterials Science (2023) Vol. 11, Iss. 6, pp. 2065-2079
Open Access | Times Cited: 18
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial
Magdalena E. Sobieszczyk, Sharon Mannheimer, Carmen A. Paez, et al.
The Lancet HIV (2023) Vol. 10, Iss. 10, pp. e653-e662
Open Access | Times Cited: 18
Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy
Christopher Chung, Sagar B. Kudchodkar, Curtis N. Chung, et al.
Antibodies (2023) Vol. 12, Iss. 3, pp. 46-46
Open Access | Times Cited: 15
The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention
Jannifer Jasmin Thavarajah, Bo Langhoff Hønge, Christian Wejse
(2024)
Open Access | Times Cited: 5
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial
Boris Jülg, Victoria E. Walker-Sperling, Kshitij Wagh, et al.
Nature Medicine (2024)
Open Access | Times Cited: 5
Antibody prophylaxis may mask subclinical SIV infections in macaques
Christopher A. Gonelli, Hannah A. D. King, Sung‐Youl Ko, et al.
Nature (2025) Vol. 639, Iss. 8053, pp. 205-213
Open Access
HIV diagnosis during acute infection: implications of long-acting preexposure prophylaxis and other evolving challenges
Tamara Elliott, Daniel Bradshaw, Sarah Fidler
Current Opinion in HIV and AIDS (2025)
Closed Access
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Tariro Dianah Chawana, Stephen R. Walsh, Lynda Stranix‐Chibanda, et al.
BMC Immunology (2025) Vol. 26, Iss. 1
Open Access
Broadly neutralizing antibodies targeting HIV: Progress and challenges
Paneerselvam Nandagopal, Amber Khan, Brian R. Lawson
Clinical Immunology (2023) Vol. 257, pp. 109809-109809
Closed Access | Times Cited: 12
Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects
Amitinder Kaur, Monica Vaccari
Viruses (2024) Vol. 16, Iss. 3, pp. 368-368
Open Access | Times Cited: 4
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives
Sharana Mahomed
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 4
Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy
Sarah Dohadwala, Matthew T. Geib, Joseph A. Politch, et al.
Frontiers in Reproductive Health (2024) Vol. 5
Open Access | Times Cited: 3
The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention
Jannifer Jasmin Thavarajah, Bo Langhoff Hønge, Christian Wejse
Viruses (2024) Vol. 16, Iss. 6, pp. 911-911
Open Access | Times Cited: 2
Complement contributes to antibody-mediated protection against repeated SHIV challenge
Benjamin S. Goldberg, David A. Spencer, Shilpi Pandey, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 20
Open Access | Times Cited: 6
Lc-Ms/Ms Method for Quantifying the Hiv-1 Broadly Neutralizing Antibody Pgt 121.414.Ls in Human Serum
Connor E. Gould, Qing Ma, Raymond Cha, et al.
(2024)
Closed Access
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Srilatha Edupuganti, Christopher B. Hurt, Kathryn E. Stephenson, et al.
The Lancet HIV (2024) Vol. 12, Iss. 1, pp. e13-e25
Closed Access
An update on long-acting agents in HIV therapy
Laura Pezzati, G Canavesi, Stefano Rusconi
Future Virology (2023) Vol. 18, Iss. 13, pp. 881-893
Closed Access | Times Cited: 1
Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial
Sharana Mahomed, Nigel Garrett, Disebo Potloane, et al.
BMJ Open (2023) Vol. 13, Iss. 8, pp. e076843-e076843
Open Access
HIV Prevention Utilizing Long-acting Injectables
Eric F. Egelund, Jessica Huston
touchREVIEWS in Infectious Diseases (2022) Vol. 1, Iss. 1, pp. 31-31
Open Access
Page 1

Scroll to top